// STATE LEGISLATION TRACKER

Kentucky HB 680 — AN ACT relating to controlled substances.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown

State: Kentucky
Bill: HB 680
Filed: 2026-02-19
Read the bill: OpenStates →
Last reviewed: 2026-06-21

Plain-English Summary

Kentucky HB680 is titled as a controlled-substances bill, but no bill text or current action details were available from the provided source. Based only on the title and subject, it does not appear to directly target compounded peptides, off-label peptide prescribing, telehealth peptide care, naturopathic or NP scope, or FDA 503A/503B compounding.

Key Points

No available text showing direct peptide restrictions
Controlled-substance changes could affect prescribing workflows
No evidence it changes 503A or 503B peptide compounding
No evidence it changes telehealth peptide prescribing
No evidence it changes NP or naturopathic scope

What to Watch For

Note Confirm the bill text once Kentucky or OpenStates publishes a readable version.

Concern If it expands controlled-substance rules, clinics may face more prescribing or monitoring steps.

Note Peptides are generally not controlled substances unless a specific product is scheduled.

Where the Bill Stands

The provided source reports that the latest action could not be refetched, and no reliable current status was available.

— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws